Truist raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $17 from $15 and keeps a Buy rating on the shares. The company reported solid Q4 results and the management introduced 2026 guidance most notable for a strong EBITDA uptick, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Truist ups Amneal Pharmaceuticals price target, says pullback great entry point
- Amneal Pharmaceuticals: Portfolio Shift to High-Margin Brands and Biosimilars Supports Buy Rating and Upside to $17 Target
- Amneal Posts Strong Q4 Results and Raises 2026 Outlook
- Options Volatility and Implied Earnings Moves Today, February 27, 2026
- Amneal Pharmaceuticals reports Q4 adjusted EPS 21c, consensus 18c